ATE364618T1 - Antikörper gegen das muc18-antigen - Google Patents
Antikörper gegen das muc18-antigenInfo
- Publication number
- ATE364618T1 ATE364618T1 AT02797516T AT02797516T ATE364618T1 AT E364618 T1 ATE364618 T1 AT E364618T1 AT 02797516 T AT02797516 T AT 02797516T AT 02797516 T AT02797516 T AT 02797516T AT E364618 T1 ATE364618 T1 AT E364618T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- muc18
- muc18 antigen
- antigen
- melanomas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34629901P | 2001-12-28 | 2001-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE364618T1 true ATE364618T1 (de) | 2007-07-15 |
Family
ID=23358784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02797516T ATE364618T1 (de) | 2001-12-28 | 2002-12-26 | Antikörper gegen das muc18-antigen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6924360B2 (de) |
| EP (1) | EP1470146B8 (de) |
| JP (1) | JP2005514425A (de) |
| AT (1) | ATE364618T1 (de) |
| AU (1) | AU2002361886A1 (de) |
| CA (1) | CA2471849A1 (de) |
| DE (1) | DE60220719T2 (de) |
| ES (1) | ES2289174T3 (de) |
| WO (1) | WO2003057838A2 (de) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2441953A1 (en) * | 2001-03-23 | 2002-10-03 | The Board Of Regents Of The University Of Texas System | Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| WO2004043405A2 (en) * | 2002-11-12 | 2004-05-27 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
| PL1745075T3 (pl) | 2004-04-21 | 2013-09-30 | Brigham & Womens Hospital Inc | Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania |
| CA2637012A1 (en) * | 2006-01-30 | 2007-08-09 | Fred Hutchinson Cancer Research Center | Sequence of stro-1 antibody variable region |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| CN102159540B (zh) * | 2008-07-21 | 2015-08-12 | 布赖汉姆妇女医院 | 与合成的β-1,6葡糖胺寡糖相关的方法和组合物 |
| US8450278B2 (en) | 2008-10-15 | 2013-05-28 | Board Of Regents, The University Of Texas System | MUC18 targeting peptides |
| MY173390A (en) * | 2009-10-23 | 2020-01-22 | Takeda Pharmaceuticals Co | Anti-gcc antibody molecules and related compositions and methods |
| HRP20191690T1 (hr) | 2012-04-27 | 2019-12-27 | Millennium Pharmaceuticals, Inc. | Molekule anti-gcc antitijela i njihova uporaba u ispitivanju osjetljivosti na gcc-ciljanu terapiju |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| CN104955847A (zh) * | 2012-12-04 | 2015-09-30 | 马里兰州大学(巴尔的摩) | HIV-1 Env结合抗体、融合蛋白及其使用方法 |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| EP3712166A1 (de) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen |
| DK3049118T3 (en) * | 2013-09-24 | 2018-08-13 | Oncoinvent As | MONOCLONAL ANTIBODY AND DERIVATIVES |
| EP3116906A1 (de) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Für lg1-3 spezifische anti-laminin4-antikörper |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI718121B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| US10906964B2 (en) | 2016-05-02 | 2021-02-02 | Prothena Biosciences Limited | Antibodies recognizing tau |
| MX2018013384A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| EP3478714A2 (de) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin-antikörper |
| JP7017013B2 (ja) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| WO2018220467A1 (en) | 2017-05-30 | 2018-12-06 | Foroogh Nejatollahi | Anti-muc18 human immunotoxin and applications thereof |
| KR102581734B1 (ko) | 2017-10-06 | 2023-09-22 | 네오토프 뉴로사이언스 리미티드 | 트랜스타이레틴의 검출 방법 |
| US12325737B2 (en) | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| SG11202104549TA (en) | 2018-11-08 | 2021-05-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| WO2020132232A2 (en) * | 2018-12-21 | 2020-06-25 | Multitude Inc. | Antibodies specific to muc18 |
| TWI851634B (zh) * | 2018-12-21 | 2024-08-11 | 大陸商沐特圖公司 | Muc18特異性抗體 |
| US12397014B2 (en) | 2019-02-05 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
| TWI859197B (zh) | 2019-03-03 | 2024-10-21 | 愛爾蘭商普羅帝納生物科學公司 | 識別ｔａｕ之抗體 |
| KR20220069982A (ko) | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
| EP4045515A4 (de) | 2019-10-18 | 2023-10-18 | The Regents Of The University Of Michigan | Biomaterialsensorsysteme |
| WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| AU2021297540A1 (en) | 2020-06-24 | 2023-02-02 | Prothena Biosciences Limited | Antibodies recognizing sortilin |
| US20240043501A1 (en) | 2020-10-15 | 2024-02-08 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| JP2024537100A (ja) | 2021-10-05 | 2024-10-10 | アムジエン・インコーポレーテツド | Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量 |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4602174A1 (de) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Auf hämatopoetische stammzellen abzielende virale partikel |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| JP2026516670A (ja) | 2023-04-20 | 2026-05-26 | アムジエン・インコーポレーテツド | 相対的な不対グリカン含有量を決定する方法 |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| EP4719352A1 (de) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipidnanopartikelformulierungen und zusammensetzungen |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| AU2024325342A1 (en) | 2023-08-14 | 2026-02-26 | Amgen Inc. | Methods for reducing yellow color |
| CN122070299A (zh) | 2023-09-15 | 2026-05-19 | 普罗塞纳生物科学有限公司 | 细胞穿透剂及其用途 |
| AU2024341632A1 (en) | 2023-09-15 | 2026-04-23 | Prothena Biosciences Limited | Compositions and methods of reducing immunogenicity and improving stability of antibodies |
| WO2025059486A1 (en) | 2023-09-15 | 2025-03-20 | Prothena Biosciences Limited | Anti-tdp-43 antibodies and uses thereof |
| WO2025059487A2 (en) | 2023-09-15 | 2025-03-20 | Othair Prothena Limited | Cell penetrating agents and uses thereof |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026090253A1 (en) | 2024-10-23 | 2026-04-30 | Amgen Inc. | Methods of determining glycan pairing content |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735210A (en) * | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) * | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5648471A (en) * | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| CA2065299C (en) * | 1989-08-09 | 2001-07-24 | Buck A. Rhodes | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5697901A (en) * | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| CA2441953A1 (en) | 2001-03-23 | 2002-10-03 | The Board Of Regents Of The University Of Texas System | Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors |
| JP2005514409A (ja) * | 2001-12-28 | 2005-05-19 | アブジェニックス・インコーポレーテッド | Ｍｕｃ１８抗原に対する抗体の使用 |
-
2002
- 2002-12-26 EP EP02797516A patent/EP1470146B8/de not_active Expired - Lifetime
- 2002-12-26 CA CA002471849A patent/CA2471849A1/en not_active Abandoned
- 2002-12-26 WO PCT/US2002/041581 patent/WO2003057838A2/en not_active Ceased
- 2002-12-26 JP JP2003558140A patent/JP2005514425A/ja active Pending
- 2002-12-26 DE DE60220719T patent/DE60220719T2/de not_active Expired - Fee Related
- 2002-12-26 AT AT02797516T patent/ATE364618T1/de not_active IP Right Cessation
- 2002-12-26 AU AU2002361886A patent/AU2002361886A1/en not_active Abandoned
- 2002-12-26 ES ES02797516T patent/ES2289174T3/es not_active Expired - Lifetime
- 2002-12-26 US US10/330,613 patent/US6924360B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60220719D1 (de) | 2007-07-26 |
| AU2002361886A1 (en) | 2003-07-24 |
| DE60220719T2 (de) | 2008-03-06 |
| US6924360B2 (en) | 2005-08-02 |
| CA2471849A1 (en) | 2003-07-17 |
| EP1470146B8 (de) | 2007-09-12 |
| ES2289174T3 (es) | 2008-02-01 |
| US20030147809A1 (en) | 2003-08-07 |
| EP1470146A4 (de) | 2005-07-13 |
| EP1470146A2 (de) | 2004-10-27 |
| EP1470146B1 (de) | 2007-06-13 |
| WO2003057838A3 (en) | 2004-03-11 |
| WO2003057838A2 (en) | 2003-07-17 |
| JP2005514425A (ja) | 2005-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60220719D1 (de) | Antikörper gegen das muc18-antigen | |
| ATE394121T1 (de) | Verwendung von antikörpern gegen das muc18- antigen | |
| WO2003057837A8 (en) | Methods for using anti-muc18 antibodies | |
| MX338122B (es) | Epitopes terapeuticos y usos de los mismos. | |
| DE60038252D1 (de) | Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3 | |
| IN2012DN00313A (de) | ||
| BR0011838A (pt) | Elementos misturadores estáticos empilhados | |
| TW200505942A (en) | Antibody molecules having specificity for human IL-1β | |
| TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
| TR200102733T2 (tr) | IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
| BRPI0411784A (pt) | anticorpos contra interleucina -22 e usos para os mesmos | |
| BG101024A (bg) | Моноклонално антитяло срещу сd44v6 | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
| EA200401341A1 (ru) | Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания | |
| DK0552296T3 (da) | Monoklonale antistoffer fra mus | |
| CY1111946T1 (el) | To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας | |
| ATE407147T1 (de) | Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein | |
| WO2004031105A3 (en) | Use of a33 antigens and jam-it | |
| NO20055741D0 (no) | Nye kjemiske forbindelser | |
| WO2004069183A3 (en) | Immune regulation based on the targeting of early activation molecules | |
| DE602004019541D1 (de) | Cycloalkyläbü kondensierte indole | |
| GB0004576D0 (en) | Proteins | |
| ATE538376T1 (de) | Herstellung polyklonaler, monospezifischer antikörper gegen die upar-varianten del4, del5 und del4+5 sowie deren verwendung für diagnostische und therapeutische zwecke | |
| AU2003225900A1 (en) | Antibody disulfide isomers, use thereof, and methods of analyzing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |